Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

e the long-term safety of pirfenidone in patients with IPF. ITMN-191 (R7227): -- In November 2008, Roche, InterMune and Pharmasset, Inc. initiated the first all-oral combination study of direct anti-virals in the absence of interferon or ribavirin, known as the INFORM-1 study. That study has completed the first dose cohort. -- On January 12, 2009, InterMune announced top-line results from a 14-day, Phase 1b study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). - After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage cohorts in the study, and was -5.4 log10 and -5.7 log10 in the best performing q12h and q8h cohorts, respectively. - Reductions in HCV RNA occurred rapidly and there was no evidence of viral rebound during ITMN-191 treatment in any cohort. - ITMN-191 was generally safe and well tolerated in the study. There were no serious adverse events or Grade 4 adverse events (AEs) during treatment with ITMN-191. AEs reported during study treatment (ITMN-191 or placebo) were predominantly mild to moderate in severity, typically consistent with the AE profile of standard of care (SOC), and none led to treatment discontinuation. Financial: -- On February 19, 2009, InterMune completed a follow-on public offering of 4,025,000 shares of common stock, including the underwriters' over-allotment, at an offer price of $16.35 per share. Net proceeds to InterMune were approximately $63.5 million after deduction of underwriting fees and other related expenses. -- The Medicines Company announced on February 25, 2009, that it had completed its tender offer for all of the outstanding shares of Targanta Therapeutics Co
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... (PRWEB) November 19, 2014 The science ... lives was shared with more than 200 primary students ... students from the University of Otago Physics Department and ... The Otago students, members of the university’s OSA/SPIE Student ... in early September, giving children from small, rural schools ...
(Date:11/21/2014)... The November 2014 issue of BioTechniques ( ... journal featuring the following articles:, , ... in the retina , DNA from fingermarks ... chromogenic substrates in zebrafish , Re-use of ... , Nuclear LC3-positive puncta in stressed cells ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris ... been dosed in its Phase 1 trial of ... for the treatment of malignant pleural mesothelioma (MPM) ... is conducting clinical trials on ADI-PEG 20, both ... for the treatment of several other indications, including ...
(Date:11/18/2014)... Sarasota, FL (PRWEB) November 17, 2014 ... novel point-of-care diagnostic tests – today announces its ... Control and Prevention’s (CDC) Get Smart About Antibiotics ... Antibiotics Week is a national campaign designed to ... local health departments, and non-profit and for-profit partners ...
Breaking Biology Technology:Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... Pa., May 7 Encorium Group, Inc. ... multinational contract research organization (CRO) that provides design, ... patient registries to many of the world,s leading ... M.D., Ph.D. has been appointed Head Consultant of ...
... EAST BRUNSWICK, N.J., May 7 Savient Pharmaceuticals, Inc. ... biologics license application (BLA) for KRYSTEXXA (TM) (pegloticase), ... patients, will be reviewed by the Arthritis Advisory Committee ... on June 16, 2009. In December, the FDA ...
... May 7 Sigma-Aldrich Corporation (Nasdaq: SIAL ) ... Lynch 2009 Healthcare Conference on Wednesday, May 13th at 2:00 ... parties may listen via live audio broadcast over the Internet ... can click the "Webcast" icon to access this file. ...
Cached Biology Technology:Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 2Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 3Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team 4Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout 2Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout 3Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout 4Sigma-Aldrich to Present at the Bank of America and Merrill Lynch 2009 Healthcare Conference on Wednesday, May 13, 2009 2
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... CHESTERFIELD, Mo. , April 22, 2013 The ... panel of experts from multiple disciplines, including farmers, media, ... questions surrounding GMOs. This discussion was moderated by CNBC ... The Food Dialogues℠: Chicago , which ...
... checked were for native Australian millipede species and were published ... and the Atlas of Living Australia , ALA. GBIF ... but disclaim any responsibility for errors in museum databases, instead ... fit for purpose. The auditing was done voluntarily by ...
... April 2013. Researchers have known for some years that the ... Arctic when the waters in its traditional habitat become too ... are now moving up as far as Spitsbergen into the ... two and a half years, biologists from the Alfred Wegener ...
Cached Biology News:CNBC Senior Analyst Ron Insana Moderates Discussion On Biotech Seeds At The Food Dialogues(SM): Chicago 2CNBC Senior Analyst Ron Insana Moderates Discussion On Biotech Seeds At The Food Dialogues(SM): Chicago 3Online biodiversity databases audited: 'Improvement needed' 2Atlantic cod in for even more stress? 2Atlantic cod in for even more stress? 3
... Acridinium NHS ester can be ... nucleic acids. The covalently bound ... chemiluminescence in the presence of ... proteins can be used as ...
... is making flow cytometry accessible to anyone in ... the latest addition to Guavas on-demand microcapillary flow ... easy to use, surprisingly affordable, very compact, and ... detection. The Guava EasyCyte Mini has all of ...
... MiniOpticon 2-color real-time PCR detection system holds 48 x ... of 48 LEDs independently excites fluorescence (470-500 nm) for ... emitted light (523-543 nm and 540-700 nm). This item ... Mini thermal cycler. System dimensions are 18 x 32 ...
... Cytomics FC 500 Series is ... with the most advanced technologies ... delivers flexible testing, powerful software ... that help researchers optimize their ...
Biology Products: